MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Lung and Upper Aerodigestive Cancer
National Cancer Institute (NCI)
Active, not recruiting ID
For more information, see NCT03300817
This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine works in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.
MUC1 Peptide-Poly-ICLC Vaccine, Laboratory Biomarker Analysis
Lung Carcinoma
Arjun Pennathur

See list of participating sites